Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
Mar 03, 2023
Mabwell's Clinical Trial Application for 9MW3911 Injection - An Innovative Drug, Accepted by NMPA
➞
Feb 27, 2023
First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND
➞
Feb 05, 2023
Accelerating Development of Mabwell's ADC Plateform: Clinical Trial Application for an Innovative Drug (9MW2921) Accepted by NMPA
➞
Jan 20, 2023
$412.5 Million Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases
➞
Jan 03, 2023
Mabwell Announces the NMPA Approval of 9MW3011 (FIC) for IND
➞
上一页
1
2
3
4